Leerink Partnrs Issues Negative Forecast for Biogen Earnings

Key Points

• Leerink Partners has revised its Q4 2025 earnings forecast for Biogen from $3.40 to $3.20 per share, while the consensus estimate for the full year is $15.83 per share.
• Biogen recently reported better-than-expected quarterly earnings of $5.47 per share, significantly exceeding the analysts' expectations of $3.93, along with a revenue of $2.65 billion.
• Analyst ratings for Biogen show a consensus of "Hold" with 11 "Buy" ratings, 20 "Hold" ratings, and 1 "Sell" rating, suggesting mixed investor sentiment.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Leerink Partnrs dropped their Q4 2025 earnings estimates for Biogen in a research note issued to investors on Monday, October 6th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings of $3.20 per share for the quarter, down from their prior estimate of $3.40. The consensus estimate for Biogen's current full-year earnings is $15.83 per share.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The business had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.32 billion. During the same quarter in the previous year, the business posted $5.28 earnings per share. The company's revenue was up 7.3% on a year-over-year basis. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

Other analysts have also recently issued reports about the stock. Royal Bank Of Canada increased their target price on shares of Biogen from $208.00 to $219.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Morgan Stanley dropped their price objective on shares of Biogen from $146.00 to $144.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. Wedbush reaffirmed a "neutral" rating and issued a $121.00 price objective on shares of Biogen in a report on Thursday, June 12th. HC Wainwright increased their price objective on shares of Biogen from $187.00 to $194.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Finally, Rothschild & Co Redburn increased their target price on shares of Biogen from $149.00 to $150.00 and gave the company a "neutral" rating in a research report on Monday. Eleven equities research analysts have rated the stock with a Buy rating, twenty have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $180.04.

Biogen Price Performance

Shares of BIIB stock opened at $152.21 on Wednesday. The company has a market capitalization of $22.32 billion, a PE ratio of 14.55, a price-to-earnings-growth ratio of 1.22 and a beta of 0.13. The firm has a fifty day simple moving average of $139.00 and a 200-day simple moving average of $130.99. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36. Biogen has a twelve month low of $110.04 and a twelve month high of $194.13.

Insider Activity

In other news, insider Priya Singhal sold 517 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the sale, the insider directly owned 5,772 shares of the company's stock, valued at $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.18% of the stock is owned by company insiders.

Hedge Funds Weigh In On Biogen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIIB. Elevation Point Wealth Partners LLC acquired a new position in Biogen during the second quarter valued at approximately $25,000. Opal Wealth Advisors LLC bought a new position in shares of Biogen during the first quarter valued at $26,000. Vision Financial Markets LLC bought a new position in shares of Biogen during the first quarter valued at $27,000. Greykasell Wealth Strategies Inc. bought a new position in shares of Biogen in the first quarter valued at about $27,000. Finally, Rothschild Investment LLC raised its holdings in shares of Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company's stock valued at $28,000 after buying an additional 88 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.